drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, lentiviral-transduced, gene-modified T-cell therapy expressing a CAR targeting the BT-001 tumor surface antigen; given via multiple IV infusions without lymphodepleting chemotherapy to redirect T cells to kill BT-001–positive solid tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express a chimeric antigen receptor that binds the BT-001 tumor surface antigen. Antigen engagement triggers CAR signaling (CD3ζ with costimulation), activating and expanding the T cells to mediate perforin/granzyme-dependent cytotoxicity and cytokine release, selectively killing BT-001–positive solid tumor cells; given as repeat IV infusions without lymphodepleting chemotherapy.
drug_name
B4T2-001 autologous CAR-T
nct_id_drug_ref
NCT06072989